Tofersen

Revision as of 20:18, 20 May 2024 by Rithish Nimmagadda (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Tofersen
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rithish Nimmagadda,MBBS.[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Tofersen is an antisense oligonucleotide that is FDA approved for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.. Common adverse reactions include he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

-Tofersen is administered intrathecally using a lumbar puncture by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.

-Recommended dose is 100 mg (15 mL) per administration

-Initiate tofersen treatment with 3 loading doses administered at 14-day intervals. [ref] A maintenance dose should be administered once every 28 days thereafter.

-Allow vial to warm to room temperature prior to administration.

-Withdraw the required dose of 15 mL (equivalent to 100 mg) from the vial; do not dilute.

-Administer within 4 hours of removal from vial.

-Prior to administration, remove approximately 10 mL of CSF.

-Administer as an intrathecal bolus injection over 1 to 3 minutes.

-Consult prescribing information for additional instructions on preparation and administration of tofersen

Off-Label Use and Dosage (Adult)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Tofersen FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Contraindications

None

Warnings

-Myelitis and Radiculitis

Serious adverse reactions of myelitis and radiculitis have been reported in patients treated with tofersen. Six patients treated with tofersen experienced myelitis or radiculitis in the clinical studies. Two patients discontinued treatment with tofersen and required symptomatic management with full resolution of symptoms. In the remaining 4 patients, symptoms resolved without discontinuation of the drug. If symptoms consistent with myelitis or radiculitis develop, diagnostic workup and treatment should be initiated according to the standard of care. Management may require interruption or discontinuation of tofersen.

-Papilledema and Elevated Intracranial Pressure

Serious adverse reactions of papilledema and elevated intracranial pressure have been reported in patients treated with tofersen. Four patients developed elevated intracranial pressure and/or papilledema. All patients received treatment with standard of care with resolution of symptoms, and no events led to discontinuation of tofersen. If symptoms consistent with papilledema or elevated intracranial pressure develop, diagnostic workup and treatment should be initiated according to the standard of care.

-Aseptic Meningitis

Serious adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) have been reported in patients treated with tofersen. One patient experienced a serious adverse reaction of chemical meningitis, which led to discontinuation of tofersen. One patient experienced a serious adverse reaction of aseptic meningitis, which did not lead to discontinuation of the drug. In addition, nonserious increases in CSF white blood cell and CSF protein have also been reported with tofersen. If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Tofersen Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Tofersen Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Tofersen Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Tofersen in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Tofersen in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Tofersen during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Tofersen in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Tofersen in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Tofersen in geriatric settings.

Gender

There is no FDA guidance on the use of Tofersen with respect to specific gender populations.

Race

There is no FDA guidance on the use of Tofersen with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Tofersen in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Tofersen in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Tofersen in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Tofersen in patients who are immunocompromised.

Administration and Monitoring

Administration

Inform patients and caregivers that tofersen could cause myelitis and radiculitis. Instruct patients and caregivers to contact their healthcare provider if symptoms consistent with these adverse reactions develop.

Inform patients and caregivers that tofersen could cause papilledema and elevated intracranial pressure. Instruct patients and caregivers to contact their healthcare provider if symptoms consistent with these adverse reactions develop.

Inform patients and caregivers that tofersen could cause aseptic meningitis. Instruct patients and caregivers to contact their healthcare provider if symptoms consistent with meningitis develop.

Monitoring

There is limited information regarding Tofersen Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Tofersen and IV administrations.

Overdosage

There is limited information regarding Tofersen overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Tofersen Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Tofersen Mechanism of Action in the drug label.

Structure

There is limited information regarding Tofersen Structure in the drug label.

Pharmacodynamics

There is limited information regarding Tofersen Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Tofersen Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Tofersen Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Tofersen Clinical Studies in the drug label.

How Supplied

There is limited information regarding Tofersen How Supplied in the drug label.

Storage

There is limited information regarding Tofersen Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Tofersen |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Tofersen |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Tofersen Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Tofersen interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

Qalsody®

Look-Alike Drug Names

There is limited information regarding Tofersen Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.